In the fourth quarter of 2020 CordenPharma announced both an expansion of non-GMP capacity at its Center of Excellence for Peptide Process Development in Frankfurt, Germany, and a major increase in upstream capacity with the introduction of a new 3,000L Solid Phase Peptide Synthesis (SPPS) vessel in CordenPharma Colorado.
 
As the next step of its growth strategy, CordenPharma has added a second 100 cm high-pressure chromatography column at CordenPharma Colorado to accommodate the continuous growth and evolution of the peptide therapeutic market.
 
“This additional column will provide the capacity to purify several tons of peptide annually, which in conjunction with our existing 100 and 80 cm columns, gives us more flexibility and redundancy to maximize supply security for all of our partners,” said Matthieu Giraud, global director of CordenPharma’s peptides, lipids and carbohydrates platform.
 
The new column is installed and will be qualified by the end of Q2 2021.